Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 10,001–10,100 of 10,906
(2021) · doi:10.1101/2021.11.01.21265737
Blattner, M., Schäfer, I., Nestoriuc, Y., Büchel, C., Scherer, M., & Oltrogge, J. H. (2026) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70372
“Side effects following a COVID-19 vaccination include systemic reactions such as cephalalgia, myalgia, chills, and fever as well as local reactions at the injection site [5, 6].”
InfluentialThe RNA World: The Best of Times, the Worst of Times
VandenDriessche, T. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.29173.tvd
Kopanos, S., Knappe, U. J., Abolmaali, N., & Feldkamp, J. (2026) · Reports — Medical Cases Images and Videos · doi:10.3390/reports9020141
“Transient cytokine release (interleukin-6, TNF-α ), endothelial activation, and immune-mediated vasculitis have been proposed mechanisms in post-vaccine inflammatory events involving the central nervous sys-tem [15,16].”
Identification and characterization of a SARS-CoV-2 M pro G23 deletion ensitrelvir-resistant mutantPreprint
Ma, Y., Ye, C., Rahisuddin, R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.30.679586
Son, B., Park, G. Y., Jeong, I., Kim, H., Lee, J., Joo, J., Lee, W., & Park, H. H. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103529
“…half-life requires repeated administration to maintain the minimum threshold of transcription factor expression needed for complete CM maturation, and elevated therapeutic doses can spark transient activation of innate pattern-recognition pathways, risking localized immunogenicity [103 – 107].”
Increasing Lipid Nanoparticle mRNA Copy Number Improves Transfection Potency
Zhang, Y., Leung, J., Cheng, J., Momeni, A., Kamanzi, A., Bido, A. T., Liao, S., Kang, E., Strong, C., Kastrup, C. J., et al. (2026) · Advanced Materials · doi:10.1002/adma.75174
Monrroy, C. S. H., & Cañarte, P. A. S. (2022) · Health Leadership and Quality of Life · doi:10.56294/hl202288
Huguet, M., Boigués, M., Sorigué, M., Blanco, J., Quirant‐Sánchez, B., Ferra, C. M., Huguet, M., Boigués, M., Morgades, M., Felip, E., et al. (2024) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2024.03.002
Lin, S.-L. (2021) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2021.40.006394
Cross-national patterns of COVID-19 vaccination coverage by vaccine type
Al-Zyoud, W. A., Erekat, D., & Abudayah, M. A. (2026) · PLOS Global Public Health · doi:10.1371/journal.pgph.0006682
Rabbani, S. A., Sharma, S., Mishra, S., & Mahtab, A. (2021) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2021/v33i24b31445
Sandoval, M. A., Li, Q., Shi, R., Giri, B. R., Yanwinitchai, S., Southard, B., Ni, H., Owens, D. E., Williams, R. O., Weissman, D., et al. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127318
Treatment for COVID-19: Current Therapy and Challenges
Bhattacharjee, A., Maity, P., Choudhuri, S., et al. (2022) · doi:10.31674/book.2022macbs.010
Persistence of Antibody Response Against SARS-CoV-2 After Vaccination
Bekti, H. S., Habibah, N., Dharmawati, I. G. A. A., Merdekawati, F., & Noviar, G. (2023) · JURNAL INFO KESEHATAN · doi:10.31965/infokes.vol21.iss4.1066
Ferrazza, G., Nucera, A., Longo, S., Ferrari, C., Mazza, A., Magrini, A., Coppeta, L., & Rizza, S. (2023) · The Open Public Health Journal · doi:10.2174/0118749445268028230921100630
Hammond, K., Bourdeau, F., Klein, M., Vinh, D. C., & Semret, M. (2024) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi-2024-0005
Çakır, Y., & Görgülü, G. S. (2023) · Türk Mikrobiyoloji Cemiyeti Dergisi · doi:10.54453/tmcd.2023.37891
Retinal vein occlusion in the general population after COVID-19 vaccination and infection
Napal, B., García-Palacios, J. D., González-Mesones, B., et al. (2023) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2023.04.031
Singal, M., Kashinath, S. K., Mustafa, S. S., Walsh, E., Vadamalai, K., & Jamshed, S. (2022) · Advances in Clinical Medical Research and Healthcare Delivery · doi:10.53785/2769-2779.1118
COVID-19 and Digestive Diseases: A Comprehensive Review on Pathophysiology and Clinical Management
Ibrahim, N. E., & Hassan, F. M. (2024) · Coronaviruses · doi:10.2174/0126667975293524240625115448
Andrews, J. R., Hermans, S., White, R. G., García‐Basteiro, A. L., Croda, J., & Cobelens, F. G. J. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.129097
Huang, L.-L., Hong, W., Hu, W.-W., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2261201
Batchi-Bouyou, A. L., Djontu, J. C., Ingoba, L. L., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3221798/v1
Importancia de la vigilancia genómica de SARS-CoV-2 en los tiempos de las vacunas contra la COVID-19
Jones-Cifuentes, N. A., Peña-López, B. O., & Rincón‐Orozco, B. (2022) · Salud UIS · doi:10.18273/saluduis.54.e:22058
Zhai, H., Gao, Y., Wan, N., Qu, Y., Li, S., Li, L., Zhao, T., Hou, Q., Sun, Y., Wu, H., et al. (2026) · Journal of Virology · doi:10.1128/jvi.00269-26
“…proven through the successful global deployment of COVID-19 mRNA vaccines targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (26, 27). mRNA vaccines can stimulate both humoral and cellular immune responses and, through host translational machinery, effectively express…”
Donkor, I. O., Lomotey, E. S., Odumang, D. A., Mohammed, A. G., Asante, I. A., Kploanyi, E. E., Noora, C. L., Addo-Lartey, A. A., Affram, Y., Frimpong, J. A., et al. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-13224-7
RetractedHatzl, S., Posch, F., Schulz, E., Uhl, B., Hodl, I., Forstner, P., Sareban, N., Moritz, M., Dreo, B., Lackner, A., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127666
Effect Measures and the Sufficient-Component Cause Model
Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.005.0001
Lee, F.-S. W., Wang, J., & Wang, C.-H. J. (2022) · Research Square · doi:10.21203/rs.3.rs-1548194/v1
Beller, N. S., Beller, M., Murmann, J. J., & Crisp, R. W. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127392
Tagawa, A. (2022) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12721 · Cited by 1
Begum, R. F., Mathew, M., Doshi, P. P., & Suresh, S. (2026) · Immunologic Research · doi:10.1007/s12026-026-09757-3
Okoro, E., Salihu, M. O., Akpila, A. S., & Giwa, A. O. (2022) · Sahel Medical Journal · doi:10.4103/smj.smj_71_21
COVID-19 vaccine insights: The news beyond the headlines
Kiley (2022) · The Journal of Family Practice · doi:10.12788/jfp.0486
Exploring the incidence and time to onset of side effects associated with the COVID-19 vaccine
Saroj, R. K., Bhutia, J. L., & Upreti, B. (2025) · Discover Social Science and Health · doi:10.1007/s44155-025-00292-4
Wilhelm, M. (2021) · Pharmacy Today · doi:10.1016/j.ptdy.2021.07.022
Novel progression on clinical therapy of COVID-19: Western and Traditional Chinese Medicines
Xiong, Y., Li, Y., & Xing, F. (2025) · Exploration of Drug Science · doi:10.37349/eds.2025.1008102
Zhu, Q., Gao, J., Gu, J., Shen, L. H., Liu, J., Song, Y., Gong, X., Chen, Y., Liao, J., He, Y., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3936498
Gottlieb, R., & Spak, C. W. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab088
Efficacy and Safety of Influenza and COVID-19 Vaccines
Kawai, N., Ikematsu, H., & Bando, T. (2025) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi.r25001
Clinical characteristics, management, and prevention of coronavirus disease 2019
Guan, W., & He, J. (2023) · Frigid Zone Medicine · doi:10.2478/fzm-2023-0019
Farrelly, C. (2026) · Oxford University Press eBooks · doi:10.1093/9780197830062.003.0012
Young, J., He, E. M., Boone, D., Luehr, J., Tasnim, K., Turner, M., Ambatipudi, M., Gonzalez, P. C., Mooney, D. J., & Koh, E. G. L. (2021) · doi:10.14293/s2199-1006.1.sor-.ppaahgk.v1
The Challenge of Evaluating Vaccine Safety and Effectiveness
Mueller, S. (2022) · Springer eBooks · doi:10.1007/978-3-031-18903-6_5
Briggs, F. B. S., Schmidt, H. K., Mateen, F. J., Buxhoeveden, S., Bebo, B. F., Fiol, J., Racke, M. K., Currie, K. M., Siefers, H., Crouthamel, S., et al. (2024) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2024.106253 · Cited by 1
Shahiwala, A. (2025) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2025.2563633 · Cited by 2
“…with adaptive clinical designs and rolling regulatory reviews facilitating iterative refinement. the test stage demonstrated >90% efficacy in large phase iii trials for both Pfizer-BioNtech’s comirnaty and moderna’s Spikevax, with pivotal publications confirming safety and effectiveness [92,93].”
Tracking the Trail of Monkeypox: From Origins to Outbreak Control
Jangir, A., Swami, A., Kumari, N. P., Kumar, H., Arya, H., Yadav, N., Kumar, D., & Bhatt, T. K. (2026) · Cell Biochemistry and Function · doi:10.1002/cbf.70239 · Cited by 1
“Approaches, including altering 5′‐ and 3′‐UTR sections, encapsulating messenger RNA in liposomes and other carriers, and enhancing production procedures, are being investigated to increase the longevity of RNA vaccines [74, 148, 151–154].”
Giang, N. T. H., Lộc, P. Q., Mai, P. P., Quang, N. N., & Giang, L. M. (2023) · Tạp chí Nghiên cứu Y học · doi:10.52852/tcncyh.v165i4.1510
Probióticos – uma espada ou um escudo no desfecho da COVID-19?
de Abreu, J. A. C., de Freitas, N. L., AZEVEDO, P. R. G., & Brandão, F. (2022) · Research Society and Development · doi:10.33448/rsd-v11i4.27165 · Cited by 1
Injection-Site Reactions Post-mRNA COVID-19 Vaccination
Lian, S. B., Choo, K. J. L., Chong, C. J., et al. (2022) · EMJ Allergy & Immunology · doi:10.33590/emjallergyimmunol/10097785
Yoon, S. K., Phillips, A. L., Zhao, H., Yan, F., Chen, D., Zhuang, Y., Thiese, M. S., Rowley, E. A. K., Mckell, J., Yates, A., et al. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2735182 · Cited by 1
Medical Evidence and Prediction
Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.003.0008
Zhong, Y., Chan, K. R., Tay, C. J. X., Chia, Z. W., Li, H. E., Siriphanitchakorn, T., Ong, E. Z., Leong, Y. S., Kang, A. Y. H., Chua, R. X. Y., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2421432/v1
Makino, H., Fukuhara, S., Okinaka, K., Shibata, M., Hattori, D., Sasaki, H., Higashiyama, R. I., Iwaki, N., Munakata, W., Yagishita, S., et al. (2025) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaf207
Distinct SARS-CoV-2 Antibody Responses Elicited by Natural Infection and mRNA VaccinationPreprint
Assis, R., Jain, A., Nakajima, R., Jasinskas, A., Kahn, S., Palma, A., Parker, D. M., Chau, A., Leung, A., Grabar, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.15.440089 · Cited by 22
Oliva‐Ariza, G., Criado, I., Fuentes‐Herrero, B., Carbonell, C., Sánchez-Gallego, J. I., López‐Bernús, A., Gutiérrez, M. L., Rolo-Ramírez, A., Bernal‐Ribes, M., Almenara-Morales, Y., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020681 · Cited by 1
Cell‑intrinsic mechanisms underlying species differences in lipid nanoparticle‑mRNA deliveryPreprint
Goihberg, P., Martyniak, K., Hickey, J., Jami‐Alahmadi, Y., Soo, P. L., Narula, J., & Neubert, H. (2026) · Research Square · doi:10.21203/rs.3.rs-9180848/v1
Safety profile following mRNA-1273 COVID-19 primary vaccination in healthy adults in Indonesia
Medise, B. E., Kaswandani, N., Putri, N. D., Leonard, E., Angkasa, P. F., Putra, A. M. M. B., Muliasari, R., Indriani, V., Yosephine, P., Sundoro, J., et al. (2026) · Global Epidemiology · doi:10.1016/j.gloepi.2026.100269
Safety and Immunogenicity of Combination of Vaccines – Covishield and Covaxin – a Pilot StudyPreprint
Attunuru, B. P. R., Reddy, P. N., Sasikala, M., Gujjarlapudi, D., Yelamanchili, S., & Reddy, D. N. (2021) · Research Square · doi:10.21203/rs.3.rs-1210542/v1
Neurological complications after covid-19 vaccination
Мухсиновна, Х. Х., Rashidova, N., & Salimjonov, J. (2023) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202312312113 · Cited by 2
Lu, X., Hayashi, H., Ishikawa, E., Takeuchi, Y., Dychiao, J. V. T., Nakagami, H., & Yamasaki, S. (2024) · eLife · doi:10.7554/elife.89999.2
The path to herd immunity: is mandatory vaccination the answer?
Cheng, S. S., & Lepe, B. A. (2021) · MIT Science Policy Review · doi:10.38105/spr.7ofzvhm6x9
Saavedra, C., Vallejo, A., Longo, F., Domingo, J. J. S., Fernández-Abad, M., Gión, M., López-Miranda, E., Martínez-Jáñez, N., Guerra, E. M., Chamorro, J., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1862721/v2
Systemic SARS-CoV-2-specific antibody responses to infection and to COVID-19 and BCG vaccinationPreprint
Claus, J., ten Doesschate, T., Taks, E., Debisarun, P. A., Smits, G. P., van Binnendijk, R. S., van der Klis, F. R. M., Verhagen, L. M., de Jonge, M. I., Bonten, M. J. M., et al. (2024) · medRxiv · doi:10.1101/2024.01.24.24301644
The challenge of COVID-19 on a teratogen information service in AustraliaPreprint
Baker, M., Fotheringham, P., Kennedy, D. S., & Cupitt, D. (2026) · Research Square · doi:10.21203/rs.3.rs-9992781/v1
A Rabies Virus Nucleocapsid-like Nanostructure Vaccine Based on Dual-Cationic Lipid Nanoparticles
Zhang, Z., Zhang, J., Mu, C., Ma, K., Gao, D., Liu, C., Lin, F., Peng, X., Si, J., Li, H., et al. (2025) · Vaccines · doi:10.3390/vaccines13121196
Kido, K., Ibaragi, K., Tanishima, M., Muramoto, Y., Nakayama, S., Ata, K., Hayashida, K., Nakamura, H., Shinmura, Y., Oda, Y., et al. (2022) · medRxiv · doi:10.1101/2022.10.27.22281603
Embracing Controversy: A Second Look at CDC Reform Efforts in the Wake of COVID-19
Keller, A. C. (2024) · Journal of Health Politics Policy and Law · doi:10.1215/03616878-11672932
Motivation of COVID-19 Vaccination Among Hospital Employees: A National SurveyPreprint
Manka, L., Kashua, D., Kwiatkowski, M., Wetterauer, C., Hammerer, P. G., & Klawonn, F. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3978569
Inflammation and Heart Failure
Kim, K., Kim, D., & Eisen, H. J. (2026) · Springer eBooks · doi:10.1007/978-3-032-12629-0_20
The Gene Sequence of the Proteins of SARS-CoV-2Preprint
Thomas, S. (2022) · Research Square · doi:10.21203/rs.3.rs-2190964/v1
PLGA‐particle‐based vaccine induces SARS‐CoV‐2‐specific antibody and T‐cell responses
Horvath, D. J., Inholz, K., Mink, D., Madel, A., Koerner, J., Horlacher, R., & Basler, M. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70423 · Cited by 1
“This first generation of COVID-19-vaccines are given via the intramuscular route, leading to systemic immunity.”
InfluentialConstruction of Lipid Nanoparticles Based on Natural Molecules for Safe and Efficient mRNA Delivery
Zhong, T., Li, H., Xu, J., Zeng, F., & Wu, S. (2026) · BioNanoScience · doi:10.1007/s12668-026-02577-7
Marino, S. M., Husak, V., & Tebaldi, T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.04.709501
Kavalibasappla, A., Nagendra, K., Lingaraj, P. H., Koppad, R., Mandi, M., Rajanna, D., & Mallikarjunappa, S. K. G. (2023) · Asian Journal of Medical Sciences · doi:10.3126/ajms.v14i1.46425
Subramani, C., & Barman, T. K. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102659
Iskander, J. K., Frost, J., Russell, S., Ahluwalia, J. S., Ward, E., Steiner, S., Thomas, D. L., & Michaud, P. R. (2021) · medRxiv · doi:10.1101/2021.11.19.21266537
Bioengineering strategies to interrogate and modulate the aging immune system
Nikolich‐Žugich, J., Wolf, M. T., Pompano, R. R., & Maisel, K. (2026) · Nature Aging · doi:10.1038/s43587-026-01187-y
“One recent example is the nanoparticle-based coronavirus disease 2019 mRNA vaccines that had unusually high efficacy, potentially at least in part due to their lymph node targeting properties 48–50 .”
Novel approaches to immuno-oncology
Chen, R., & Su, F. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00047-3
Roslan, M., Nisfu, F. R. M., Arzmi, M. H., Wahab, R. A., & Zainuddin, N. (2023) · Malaysian Journal of Medical Sciences · doi:10.21315/mjms2023.30.4.2 · Cited by 2
Wang, S., Zhong, Y., Wang, C., Tian, M., Bennett, J. L., Bliss‐Moreau, E., Xue, Y., Yu, C., Hou, X., Zheng, Y. Y., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2538147123 · Cited by 2
Why would a Black man volunteer for a government-funded science experiment?
Nduom, E. K.-E. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100788
Association between COVID-19 vaccine efficacy and epidemic force of infection
Xu, J., Halloran, M. E., Moore, M., Zhang, L., Hyrien, O., Luedtke, A. R., Sahly, H. M. E., Baden, L. R., Goepfert, P., Gray, G., et al. (2026) · npj Vaccines · doi:10.1038/s41541-026-01374-3 · Cited by 1
Self-citationKahn, R. J., Villar, S. S., Dean, N. E., & Lipsitch, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-48408-7_32 · Cited by 1
Ioannou, G. N., Locke, E. R., Green, P. K., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4003207
Hayany, B. E., Alahyane, A., & Lafhal, K. (2025) · IGI Global eBooks · doi:10.4018/979-8-3693-6730-8.ch012
Dermatological adverse effects of COVID-19 vaccines
Akdaş, E., & İlter, N. (2022) · TURKDERM · doi:10.4274/turkderm.galenos.2022.57224 · Cited by 1
Impact of New COVID-19 Variant on Stroke, Thrombosis and Neurological Impairment
Das, R., Agrawal, S., Singh, N., Singh, K., & Tripathi, A. K. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002798
Koizumi, N., Hirai, T., Kano, J., Sato, A., Suzuki, Y., Sasaki, A., Nomura, T., & Utoguchi, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910679
Marconato, M., Jäger, S., Tegeler, C. M., Hackenbruch, C., Salih, H. R., Walz, J. S., Federmann, B., & Heitmann, J. S. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1844041
la Vega, R. E. D. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20230621rv
Finberg, R. W. (2021) · The Conversation · doi:10.64628/aai.gx96xwguf
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.